Alnylam Pharmaceuticals, Inc.
Asset & Liabilities Breakdown
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
FY2010
FY2009
Asset Breakdown FY2025
Total Assets: $4.97B
Liabilities Breakdown FY2025
Total Liabilities: $4.18B
Asset Breakdown
Total Assets: $4.97B
| Line Item | Value | % of Total |
|---|---|---|
| Cash & Equivalents | $1.66B | 33.4% |
| Accounts Receivable | $777.6M | 15.7% |
| Inventory | $82.7M | 1.7% |
| Property, Plant & Equipment | $513.1M | 10.3% |
| Goodwill | $0 | 0.0% |
| Intangible Assets | $0 | 0.0% |
| Other Assets | $1.94B | 39.0% |
Liabilities Breakdown
Total Liabilities: $4.18B
| Line Item | Value | % of Total |
|---|---|---|
| Accounts Payable | $115.7M | 2.8% |
| Long-Term Debt | $0 | 0.0% |
| Other Liabilities | $4.06B | 97.2% |